Trial Profile
A Phase I, Single-Center, Single Dose Study to Evaluate the Effect of Food, Gender, and Age on Safety and Pharmacokinetic Profiles of SUVN-911 Tablets Orally Administered in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Ropanicant (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Suven Life Sciences
- 13 Aug 2022 Results from two clinical studies (NCT03155503 and NCT03551288) assessing safety, tolerability and pharmacokinetics of ropanicant after single and multiple ascending doses in healthy subjects published in the Clinical Drug Investigation
- 08 Aug 2018 Status changed from recruiting to completed.
- 13 Jun 2018 New trial record